Welcome to our dedicated page for HFLO news (Ticker: HFLO), a resource for investors and traders seeking the latest updates and insights on HFLO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HFLO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HFLO's position in the market.
HeartFlow Holding, Inc., a leader in precision heart care, announced the appointment of Timothy Barabe to its Board of Directors on January 18, 2022. Barabe brings over 30 years of experience in the life sciences sector, having held key financial roles at Affymetrix and Human Genome Sciences. His addition is expected to provide valuable insights as the company enters a new growth phase. HeartFlow's technology, including its non-invasive FFRct Analysis, has already benefited over 100,000 patients globally, making it a pivotal player in heart disease diagnosis.
HeartFlow has submitted a 510k premarket application to the FDA for enhanced cardiac analysis tools, including advanced anatomic assessment and plaque evaluation, to its HeartFlow FFRct Analysis. These innovations aim to provide physicians with comprehensive insights into coronary artery disease, improving diagnostic accuracy and efficiency. Internal studies indicate a 35% increase in repeatability and a 47% rise in reproducibility for the new assessment compared to expert evaluations. HeartFlow remains committed to pioneering precision heart care through AI-driven technologies.
HeartFlow has appointed Dr. Wayne J. Riley to its Board of Directors, enhancing its leadership with his extensive healthcare experience. Currently the President of SUNY Downstate Health Sciences University, Dr. Riley brings a wealth of knowledge from key positions, including his past role as President and CEO of Meharry Medical College. He aims to advance HeartFlow's AI-enabled analysis technology, which has significantly benefited over 100,000 patients. This leadership change is pivotal as HeartFlow continues expanding its innovative coronary care solutions.
HeartFlow, a leader in precision heart care, will participate in two virtual investor conferences: the Stifel Healthcare Conference on November 17, 2021, featuring a Fireside Chat at 1:20 pm ET, and the Canaccord Genuity MedTech Forum on November 18, 2021, with 1x1 meetings. Investors can access the Fireside Chat via the company’s website. HeartFlow's innovative technology utilizes AI for non-invasive heart assessments and is available in major markets, including the US, UK, Canada, Europe, and Japan.
HeartFlow, a leader in precision heart care, announced a national payment rate of $930.34 for the HeartFlow FFRct Analysis in office-based settings, set to take effect on January 1, 2022. This decision by the Centers for Medicare & Medicaid Services (CMS) aims to enhance access for Medicare patients with coronary artery disease (CAD). The HeartFlow Analysis is already reimbursed at $950.50 in hospital outpatient settings. Furthermore, new chest pain guidelines recommend the HeartFlow Analysis as a valuable diagnostic tool for CAD.
HeartFlow has initiated the REVEALPLAQUE trial to assess its innovative non-invasive plaque detection technology aimed at reducing heart attack risks. The trial, which will enroll 250 patients across the U.S. and Japan, seeks to compare HeartFlow’s method with the traditional intravascular ultrasound imaging. Lead investigators emphasize the importance of early identification of plaque burden to prevent heart attacks. HeartFlow technology utilizes deep learning algorithms trained on over 15 million coronary CT images, currently in investigational use only.
